The post USD/JPY consolidates amid hawkish BoJ signals – OCBC appeared on BitcoinEthereumNews.com. USD/JPY steadied after BoJ Governor Ueda signaled a possible December rate hike, lifting market expectations to an 81% probability. Pair was last seen at 155.98 levels, OCBC’s FX analysts Frances Cheung and Christopher Wong note. December rate hike odds surge to 81% “USD/JPY consolidated after the recent slippage, owing to hawkish shift in BoJ rhetoric. Market pricing for December hike (19 December MPC meeting) has also swung up to 81% probability. Governor Ueda’s speech yesterday was the trigger as he highlighted that BoJ will consider the pros and cons of raising the policy interest rate. He said that real rate is very low and a hike would be an adjustment of the degree of easing (i.e. conditions still accommodative).” “He also said that the likelihood of the BoJ’s economic outlook being realized is rising. Ueda’s speech appears to be a ‘game-prep’ ahead of potential hike, making Dec or Jan meeting highly plausible. That said, comes the next question if this is a one hike and another long wait. We look for December hike. But any sustained JPY recovery would likely need BoJ to follow through with stronger guidance and for policymakers to demonstrate fiscal prudence. “ “A softer USD environment will definitely be most helpful. Daily momentum is mild bearish while RSI fell. Risks skewed to the downside. Support at 155.30 levels (21 DMA), 154.40 (76.4% fibo) and 151.60 (61.8% fibo retracement of 2025 high to low, 50 DMA). Resistance at 156.70, 157.90 and 158.87 (previous high in 2025).” Source: https://www.fxstreet.com/news/usd-jpy-consolidates-amid-hawkish-boj-signals-ocbc-202512020859The post USD/JPY consolidates amid hawkish BoJ signals – OCBC appeared on BitcoinEthereumNews.com. USD/JPY steadied after BoJ Governor Ueda signaled a possible December rate hike, lifting market expectations to an 81% probability. Pair was last seen at 155.98 levels, OCBC’s FX analysts Frances Cheung and Christopher Wong note. December rate hike odds surge to 81% “USD/JPY consolidated after the recent slippage, owing to hawkish shift in BoJ rhetoric. Market pricing for December hike (19 December MPC meeting) has also swung up to 81% probability. Governor Ueda’s speech yesterday was the trigger as he highlighted that BoJ will consider the pros and cons of raising the policy interest rate. He said that real rate is very low and a hike would be an adjustment of the degree of easing (i.e. conditions still accommodative).” “He also said that the likelihood of the BoJ’s economic outlook being realized is rising. Ueda’s speech appears to be a ‘game-prep’ ahead of potential hike, making Dec or Jan meeting highly plausible. That said, comes the next question if this is a one hike and another long wait. We look for December hike. But any sustained JPY recovery would likely need BoJ to follow through with stronger guidance and for policymakers to demonstrate fiscal prudence. “ “A softer USD environment will definitely be most helpful. Daily momentum is mild bearish while RSI fell. Risks skewed to the downside. Support at 155.30 levels (21 DMA), 154.40 (76.4% fibo) and 151.60 (61.8% fibo retracement of 2025 high to low, 50 DMA). Resistance at 156.70, 157.90 and 158.87 (previous high in 2025).” Source: https://www.fxstreet.com/news/usd-jpy-consolidates-amid-hawkish-boj-signals-ocbc-202512020859

USD/JPY consolidates amid hawkish BoJ signals – OCBC

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

USD/JPY steadied after BoJ Governor Ueda signaled a possible December rate hike, lifting market expectations to an 81% probability. Pair was last seen at 155.98 levels, OCBC’s FX analysts Frances Cheung and Christopher Wong note.

December rate hike odds surge to 81%

“USD/JPY consolidated after the recent slippage, owing to hawkish shift in BoJ rhetoric. Market pricing for December hike (19 December MPC meeting) has also swung up to 81% probability. Governor Ueda’s speech yesterday was the trigger as he highlighted that BoJ will consider the pros and cons of raising the policy interest rate. He said that real rate is very low and a hike would be an adjustment of the degree of easing (i.e. conditions still accommodative).”

“He also said that the likelihood of the BoJ’s economic outlook being realized is rising. Ueda’s speech appears to be a ‘game-prep’ ahead of potential hike, making Dec or Jan meeting highly plausible. That said, comes the next question if this is a one hike and another long wait. We look for December hike. But any sustained JPY recovery would likely need BoJ to follow through with stronger guidance and for policymakers to demonstrate fiscal prudence. “

“A softer USD environment will definitely be most helpful. Daily momentum is mild bearish while RSI fell. Risks skewed to the downside. Support at 155.30 levels (21 DMA), 154.40 (76.4% fibo) and 151.60 (61.8% fibo retracement of 2025 high to low, 50 DMA). Resistance at 156.70, 157.90 and 158.87 (previous high in 2025).”

Source: https://www.fxstreet.com/news/usd-jpy-consolidates-amid-hawkish-boj-signals-ocbc-202512020859

Market Opportunity
SURGE Logo
SURGE Price(SURGE)
$0.01599
$0.01599$0.01599
-3.79%
USD
SURGE (SURGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
Why YouCam AI API is the Secret Weapon for E-Commerce Startups

Why YouCam AI API is the Secret Weapon for E-Commerce Startups

 The New Standard of Personalized Shopping In an era where digital engagement dictates market share, the transition from “browsing” to “buying” depends on confidence
Share
Techbullion2026/03/25 14:34
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26